Three Possible Scenarios for MFN Implementation in the US: What Can Pharma Expect and What Are the Possible Strategies to Protect Revenue

Just over a year ago, US President Donald Trump signaled his intent to introduce international reference pricing (IRP) for medicines in the US through the May 2025 Most Favored Nation (MFN) executive order. Based on GlobalData's extensive repository of IRP knowledge and daily tracking of pricing and reimbursement developments around the world, in this strategic report GlobalData explores alternative scenarios for MFN implementation and what these mean for the pharmaceutical industry, with a particular focus on how to protect pharma revenue under the different scenarios.